OCS

Oculis Holding AG

Healthcare
Biotechnology
$487M market cap

Forecast run · Oct 29, 2026Upside rank 293 of 3,186

Model Signal

ForecastQ Daily Probabilities

51.4%

34.7%

36.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$7.90

Price target$36.75

Implied move+365.2%

Analysts9

ForecastQ Portfolios

Healthcare Healthcare signal →

Company Profile

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.